Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10506849 | 0.85 | DRD2 (0.43) | GABRA1GABRB2HRH3MTNR1AABCB1 | |
| SCHEMBL10256487 | 0.78 | HRH3 (0.59) | GABRA1GABRB2HRH3MTNR1AABCB1 | |
| SCHEMBL7435365 | 0.77 | MTNR1A (0.50) | MTNR1ACYP19A1MAOBCYP3A4NPC1 | |
| SCHEMBL7445863 | 0.77 | MTNR1A (0.44) | MTNR1ACYP19A1MAOBCYP3A4NPC1 | |
| SCHEMBL13799417 | 0.77 | HRH3 (0.54) | GABRA1GABRB2HRH3MTNR1AABCB1 | |
| SCHEMBL31258122 | 0.76 | MTNR1A (0.56) | GABRA1GABRB2MTNR1ACYP19A1MAPT | |
| SCHEMBL29443014 | 0.76 | GLS (0.56) | GABRA1GABRB2HRH3MTNR1AABCB1 | |
| SCHEMBL4455342 | 0.76 | GLS (0.56) | GABRA1GABRB2HRH3MTNR1AABCB1 | |
| SCHEMBL31258111 | 0.76 | MTNR1A (0.56) | GABRA1GABRB2MTNR1ACYP19A1MAPT | |
| SCHEMBL10257134 | 0.76 | HRH3 (0.60) | GABRA1GABRB2HRH3MTNR1AGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283340-B2 | Treatment or prophylaxis of proliferative conditions | The University of the University of Dundee (GB) | 2012-10-09 | — | — | US | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | GABRA1 2605/4885GABRB2 1203/4885HRH3 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.